Clinical trials: Proteinuria
Biopsy-confirmed IgA Nephropathy, Proteinuria Less Than 0.5 g Per Day
Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial
Immunoglobulin A (IgA) nephropathy is the most common type of primary glomerulonephritis in the world. The treatment of IgA nephropathy with normal renal function and minimal proteinuria is unknown.
- Conditions
- Biopsy-confirmed IgA Nephropathy, Proteinuria Less Than 0.5 g Per Day, Normal Blood Pressure, Serum Creatinine Below 120 Umol/l
- Trial name
- NCT01225445
- Testing
- Ramipril
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong
Albuminuria, Chronic Kidney Diseases
Improving Albuminuria Screening Compliance Using a Smartphone Urinalysis Kit
This study will test the effectiveness of mailed, smartphone urinalysis kits to improve albuminuria screening compliance and detection of albuminuria.
- Conditions
- Albuminuria, Chronic Kidney Diseases, Cardiovascular Diseases, Hypertension
- Trial name
- NCT03470701
- Testing
- Mailed Urinalysis Smartphone Kit
- Where
- United States
- Volunteers
- 999 people
- Sponsor
- Geisinger Clinic
Type 2 Diabetes With Nephropathy
Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy
Activation of renin-angiotensin plays a crucial role diabetic nephropathy. Angiotensin converting enzyme inhibitor (ACEI) and Angiotensin I receptor blocker (ARB) has been shown renoprotection whether it was used alone or in…
- Trial name
- NCT00949351
- Testing
- Aliskiren 300mg/d
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- Lerdsin General Hospital
Chronic Kidney Disease, Proteinuria
Optimalization of Nephroprotection Using Atorvastatin (Sortis)
The main purpose of the study is find whether the addition of statin (Atorvastatin) to dual renin-angiotensin-aldosterone system blockade involving angiotensin converting enzyme inhibitor and AT-1 angiotensin II receptor blocker…
- Trial name
- NCT00572312
- Testing
- atorvastatin (Sortis) 40 mg
- Sponsor
- Medical University of Gdansk
Lupus Nephritis, Proteinuria
Velcade for Proliferative Lupus Nephritis
The primary objective is to test the safety and efficacy of Velcade to induce remission in WHO class III/IV/V lupus nephritis that are refractory to standard medications.
- Conditions
- Lupus Nephritis, Proteinuria, Hematuria
- Trial name
- NCT01169857
- Testing
- Velcade
- Where
- United States
- Sponsor
- The Rogosin Institute
Paroxysmal Nocturnal Hemoglobinuria (PNH)
A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH
This study will be the initial exploration of pegcetacoplan in patients with PNH. The assessments of the safety, tolerability, PK, and PD following administration of single and multiples doses of pegcetacoplan will guide…
- Trial name
- NCT02264639
- Testing
- Pegcetacoplan
- Where
- 7 sites in United States
- Volunteers
- 9 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Henoch Schönlein Purpura Nephritis
Finerenone Therapy for Pediatric HSPN With Mild Proteinuria
Henoch-Schönlein purpura nephritis (HSPN) is the most common secondary glomerular disease in children. About 40% of HSPN cases are accompanied by mild proteinuria, and some of them progress to end-stage renal disease.
- Trial name
- FICHSPN (NCT07315191)
- Testing
- ACEI / ARB+finerenone, ACEI/ARB
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Capital Institute of Pediatrics, China
Chronic Kidney Diseases, Hypertension
Remote Ischaemic Conditioning on Blood Pressure Control in Chronic Kidney Disease Patients
Chronic kidney disease (CKD) is one of the leading causes of death and disability in Singapore and worldwide. Hypertension is commonly inadequately controlled in patients with CKD and this is associated with CKD progression and…
- Conditions
- Chronic Kidney Diseases, Hypertension, Cardiovascular Diseases
- Trial name
- ERIC-BP-CKD (NCT03236350)
- Testing
- Active autoRIC® (CRIC Treatment)
- Where
- Singapore
- Volunteers
- 85 people
- Sponsor
- Singapore General Hospital
Diabetic Kidney Disease (DKD)
Safety and Efficacy of the Combination Therapy of Fucoidan / Fucoxanthin / L-carnitine in Patients With Diabetic Nephropathy.
The purpose of this open-label, preliminary, proof-of-concept clinical trial is to evaluate the efficacy and safety of The purpose of this open-label, preliminary, proof-of-concept clinical trial is to evaluate the efficacy and…
- Trial name
- NCT07804641
- Testing
- Oligo-fucoidan, Fucoxanthin, L-carnitine Formula, Zinc yeast (FFL)
- Where
- Taiwan
- Volunteers
- 63 people
- Sponsor
- Taipei Medical University WanFang Hospital
Proteinuria
Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan
Losartan, an angiotensin II receptor blocker, has already been established as a treatment for diabetic nephropathy due to its ability to reduce blood pressure and mitigate the progression of kidney damage.
- Trial name
- NCT06491940
- Testing
- Losartan, Losartan + Hydrochlorothiazide
- Where
- Pakistan
- Volunteers
- 234 people
- Sponsor
- RESnTEC, Institute of Research
Diabetic Nephropathy
Study on the Efficacy and Safety of a Novel Tripterygium Wilfordii Preparation in Reducing Proteinuria in Patients With Diabetic Nephropathy
The investigators designed a randomized parallel controlled clinical study, selected 98 cases of diabetic nephropathy patients with urinary protein > 1g, randomly assigned into the Kunxian capsule + irbesartan group or irbesartan…
- Trial name
- NCT04981613
- Testing
- Kunxian capsule
- Where
- China
- Volunteers
- 80 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Hypertension, Diabetes Mellitus
Rationale and Design for Shiga Microalbuminuria Reduction Trial
The purpose of this trial are to evaluate the reduction of urinary albumin excretion by an angiotensin receptor blocker (ARB), valsartan, in comparison with a calcium channel blocker (CCB), amlodipine, in Japanese hypertensive…
- Conditions
- Hypertension, Diabetes Mellitus, Albuminuria
- Trial name
- NCT00202618
- Testing
- Valsartan, Amlodipine
- Where
- Japan
- Volunteers
- 160 people
- Sponsor
- Shiga University
Albuminuria, Type 2 Diabetes Mellitus (T2DM)
Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, for the early regression of albuminuria in…
- Conditions
- Albuminuria, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Diseases
- Trial name
- NCT07667517
- Testing
- Finerenone (BAY 94-8862)
- Where
- 13 sites in China
- Volunteers
- 148 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes
Examine red and white blood cells of PNH patients with bone marrow failure syndromes.
- Trial name
- EXPLORE (NCT01192425)
- Volunteers
- 5,580 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Chronic Kidney Disease
Correlation of Urinary Kallikrein With Cytokines, Proteinuria and Renal Function in Chronic Renal Disease Patients
Urinary kallikrein excretion is known to increase in patients with nephrotic syndrome and sick cell disease, but decrease in patients with chronic kidney disease or uremia.
- Trial name
- NCT00395005
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Diabetes, Proteinuria
Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria
The study will look at the effect of 30 days of treatment of 15 diabetics with proteinuria with N-acetylcysteine ( Mucomyst ) at a dose of 1 gm twice a day by mouth.
- Trial name
- NCT00493727
- Testing
- N-acetylcysteine(Mucomyst)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- US Department of Veterans Affairs
Type 2 Diabetic Nephropathy
Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy
The investigators hypothesize that, LPD supplemented with ketoanalogs will reduce urine podocyte loss and lower the angiotensinogen level in the urine.
- Trial name
- NCT01300273
- Testing
- Compound α-Ketoacid Tablet
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Glomerulonephritis
Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis
This study aims to assess the effect of finerenone on proteinuria and GFR progression in patients with non-diabetic glomerulonephritis.
- Trial name
- NCT06835322
- Testing
- Finerenone
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Alexandria University
Proteinuria
Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients
This study is a prospective, multicenter, parallel-controlled clinical trial designed to evaluate the therapeutic efficacy of Huaier Granules for proteinuria occurring in lung cancer patients undergoing treatment with either…
- Trial name
- NCT07358520
- Testing
- Huaier Granule, Anlotinib and Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Fudan University
We Searched for the Effects of Calcium Channel Blocker Amlodipine on the Clinical and Laboratory Parameters of Diabetic Patients With Proteinuria.
Effect of Calcium Channel Blocker on the Serum Fibrobalst Growth Factor-23 (FGF-23) Levels in Type-2 Diabetic Patients With Proteinuria Purpose
In recent years, diabetic nephropathy, which may lead to dialysis treatment, is the most prevalent underlying disease of people in developed countries.
- Trial name
- NCT01738945
- Testing
- Amlodipine
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people
- Sponsor
- Gulhane School of Medicine